Best of the Week
Most Popular
1. Stock Markets and the History Chart of the End of the World (With Presidential Cycles) - 28th Aug 20
2.Google, Apple, Amazon, Facebook... AI Tech Stocks Buying Levels and Valuations Q3 2020 - 31st Aug 20
3.The Inflation Mega-trend is Going Hyper! - 11th Sep 20
4.Is this the End of Capitalism? - 13th Sep 20
5.What's Driving Gold, Silver and What's Next? - 3rd Sep 20
6.QE4EVER! - 9th Sep 20
7.Gold Price Trend Forecast Analysis - Part1 - 7th Sep 20
8.The Fed May “Cause” The Next Stock Market Crash - 3rd Sep 20
9.Bitcoin Price Crash - You Will be Suprised What Happens Next - 7th Sep 20
10.NVIDIA Stock Price Soars on RTX 3000 Cornering the GPU Market for next 2 years! - 3rd Sep 20
Last 7 days
Market 2020 vs 2016 and 2012 - 22nd Nov 20
Gold & Silver - Adapting Dynamic Learning Shows Possible Upside Price Rally - 22nd Nov 20
Stock Market Short-term Correction - 22nd Nov 20
Stock Market SPY/SPX Island Setups Warn Of A Potential Reversal In This Uptrend - 21st Nov 20
Why Budgies Make Great Pets for Kids - 21st Nov 20
How To Find The Best Dry Dog Food For Your Furry Best Friend?  - 21st Nov 20
The Key to a Successful LGBT Relationship is Matching by Preferences - 21st Nov 20
Stock Market Dow Long-term Trend Analysis - 20th Nov 20
Margin: How Stock Market Investors Are "Reaching for the Stars" - 20th Nov 20
World’s Largest Free-Trade Pact Inspiration for Global Economic Recovery - 20th Nov 20
Dating Sites Break all the Stereotypes About Distance - 20th Nov 20
THE STOCK MARKET BIG PICTURE - Video - 19th Nov 20
Reasons why Bitcoin is Treading at it's Highest Level Since 2017 and a Warning - 19th Nov 20
Media Celebrates after Trump’s Pro-Gold Fed Nominee Gets Blocked - 19th Nov 20
DJIA Short-term Stock Market Technical Trend Analysis - 19th Nov 20
Demoncracy Ushers in the Flu World Order How to Survive and Profit From What Is Coming - 19th Nov 20
US Bond Market: "When Investors Should Worry" - 18th Nov 20
Gold Remains the Best Pandemic Insurance - 18th Nov 20
GPU Fan Not Spinning FIX - How to Easily Extend the Life of Your Gaming PC System - 18th Nov 20
Dow Jones E-Mini Futures Tag 30k Twice – Setting Up Stock Market Double Top - 18th Nov 20
Edge Computing Is Leading the Next Great Tech Revolution - 18th Nov 20
This Chart Signals When Gold Stocks Will Explode - 17th Nov 20
Gold Price Momentous ally From 2000 Compared To SPY Stock Market and Nasdaq - 17th Nov 20
Creating Marketing Campaigns Using the Freedom of Information Act - 17th Nov 20
ILLEGITIMATE PRESIDENT - 17th Nov 20
Stock Market Uptrend in Process - 17th Nov 20
How My Friend Made $128,000 Investing in Stocks Without Knowing It - 16th Nov 20
Free-spending Biden and/or continued Fed stimulus will hike Gold prices - 16th Nov 20
Top Cheap Budgie Toys - Every Budgie Owner Should Have These Safe Bird Toys! - 16th Nov 20
Line Up For Your Jab to get your Covaids Freedom Pass and a 5% Work From Home Tax - 16th Nov 20
You May Have Overlooked These “Sleeper” Precious Metals - 16th Nov 20
Demystifying interesting facts about online Casinos - 16th Nov 20
What's Ahead for the Gold Market? - 15th Nov 20
Gold’s Momentous Rally From 2000 Compared To Stock Market SPY & QQQ - 15th Nov 20
Overclockers UK Quality of Custom Gaming System Build - OEM Windows Sticker? - 15th Nov 20
UK GCSE Exams 2021 CANCELLED! Grades Based on Mock Exams and Teacher Assessments - 15th Nov 20
Global "Debt Mountain": Beware of This "New Peak" - 13th Nov 20
Overclocking Zen 3 Ryzen 5600x, 5800x, 5900x and 5950x to 4.7ghz All Cores Cinebench R20 Scores - 13th Nov 20
Is Silver Leading Bitcoin or is Bitcoin Leading Silver? - 13th Nov 20
How Elliott Waves Simplify Your Technical Analysis - 13th Nov 20
How to buy Bitcoins using debit/credit card? - 13th Nov 20
Will COVID Vaccine Kill Gold and Silver? - 12th Nov 20
Access to Critical Market Reports - 12th Nov 20
Stock Market Dow Futures Reach 30,000 on News of COVID-19 Vaccine Trials Success - 12th Nov 20
8 Terms & Conditions You Must Know Before Asking For Life Insurance Policy Quotes - 12th Nov 20
Gold Stocks Post 2020 US Election Outlook - 11th Nov 20
Champions’ League Group Stage Draw: All You Need To Know - 11th Nov 20
Stock Market Secular Trend - 11th Nov 20
Stock Market Correction Curtailed by US Election - 11th Nov 20
What Causes a Financial Bubble? - 11th Nov 20
Ryzen 9 5900X RTX 3080 - Scan.co.uk vs Overclockers.co.uk UK Custom PC System Builder Review - 10th Nov 20
Killing Driveway Weeds FAST with a Pressure Washer - Saving Block Paving from LOTS of WEEDs - 10th Nov 20
Trump Fired, Biden Hired, What Next?  - 10th Nov 20
Looking for a Personal Loan? Here Is What You Have To Know  - 10th Nov 20

Market Oracle FREE Newsletter

How to Get Rich Investing in Stocks by Riding the Electron Wave

Is TamiFlu a Scam?

Politics / Global Pandemic Dec 08, 2009 - 11:47 AM GMT

By: Nadeem_Walayat

Politics

The NHS has spent more than £500 million on TamiFlu on the premise that it will prevent the transmission of flu and hospitalisation of Swine Flu patients. To help disburse millions of dosages costing £70 each, the NHS introduced a National Flu helpline during mid 2009 and an online service which has allowed millions of patients to obtain Tami-flu prescription authorisation after just a few mouse clicks.


However Channel 4 News is now reporting that the key paper on which the effectiveness of TamiFlu makers Roche claims are based are being questioned by scientists as the drug maker is apparently refusing to make the vital data available to scientists for peer review.

Channel 4 reports further that other studies on the efftiveness of Swine flu do not stand up to clinical research - New doubts over Tamiflu

Governments around the world stockpiled supplies. In the UK alone the estimated bill for Tamiflu is approaching half a billion pounds.

Tonight Channel 4 News can reveal that serious scientific questions are being raised over the evidence base for Tamiflu.

Scientists we have spoken to say they have been unable to judge and properly test some of the claims made about the antiviral by its makers, Roche.

Claims about the drug's effectiveness in reducing hospitalisations have been a key factor in decisions by governments around the world to stockpile Tamiflu (oseltamivir). Manufacturer Roche estimates that sales of Tamiflu this year will reach £1.6bn.

Tamiflu's benefits are well-publicised. Advocates say it reduces the chance of flu being transmitted in the first place, and that once someone has become infected it shortens the duration of the illness. Today's review confirms these findings.

But the drug is also credited with reducing complications and hospitalisations in those who develop full-blown flu. In a recent interview Roche Pharmaceuticals CEO William Burns said: "What Tamiflu can do is actually reduce hospitalisations by more than 60 per cent, which is really important if we are in the midst of a major pandemic."

This is the claim now under scrutiny. The investigation by Channel 4 News and the British Medical Journal (BMJ) has discovered that an independent team of scientists has been unable to verify the scientific evidence-base to support it.

The review, commissioned in July by the NHS and published today at BMJ.com, was conducted by the Cochrane Collaboration - a worldwide group of scientists and researchers that reviews medical research. They are internationally recognised for their work.

Speaking on Chanenl 4 News, Dr Tom Jefferson, one of the Cochrane reviewers said: "This is not just any drug, this is a public health drug which is recommended by governments...  and the World Health Organisation - and has been recommended for some years."

Much of the Cochrane team's work has looked at the leading piece of clinical research supporting claims that Tamiflu reduces hospitalisations. This research was authored by swiss scientist Professor Laurent Kaiser.

His research, based on 10 clinical trials set up by Roche found that Tamiflu reduced by 59 per cent the number of people with flu who ended up in hospital. Roche have repeatedly referred to Professor Kaiser's paper when talking about Tamiflu's ability to reduce hospitalisations.

The study released today acknowledges that Tamiflu has a modest effect in reducing symptoms and duration of illness in otherwise healthy adults by about one day, but says there is insufficient published data to independently confirm  its effects on reducing complications leading to hospitalisations .

When the Cochrane reviewers approached Professor Kaiser for the original data in order to verify his conclusions, he said he didn't have it and referred them to  Roche. However, following detailed communication with the company, Roche did not supply the Cochrane team with the complete data they had requested and they were unable to verify the paper's findings.

Because they were unable to independently verify this data, the Cochrane review disregarded Kaiser’s paper from their analysis of the scientific evidence base supporting Tamiflu’s effectiveness in reducing complications.  This removes a key plank of evidence supporting a claim repeatedly made by Roche and governments like ours.

And without this study, the reviewers came to a stark conclusion. Dr Jefferson told Channel 4 News: "We didn't find any convincing evidence that Tamiflu affects complications such as as hospitalisations and chest infections."

Source:

By Nadeem Walayat
http://www.marketoracle.co.uk

Copyright © 2005-09 Marketoracle.co.uk (Market Oracle Ltd). All rights reserved.

Nadeem Walayat has over 20 years experience of trading derivatives, portfolio management and analysing the financial markets, including one of few who both anticipated and Beat the 1987 Crash. Nadeem's forward looking analysis specialises on the housing market and interest rates. Nadeem is the Editor of The Market Oracle, a FREE Daily Financial Markets Analysis & Forecasting online publication. We present in-depth analysis from over 400 experienced analysts on a range of views of the probable direction of the financial markets. Thus enabling our readers to arrive at an informed opinion on future market direction. http://www.marketoracle.co.uk

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any trading losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors before engaging in any trading activities.

Nadeem Walayat Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules